– African genomics startup 54gene has raised $25m in Series B funding.
– Pan-African venture capital firm Cathay AfricInvest Innovation Fund led this round.
– Lead investor from the company’s Series A funding, Adjuvant Capital, invested once again with participation from other VCs including KdT Ventures, Plexo Capital, Endeavor Catalyst and Ingressive Capital.
– The company has raised a total of $45m since its inception.

– Mammoth Biosciences has secured $195m in financing, joining the select ranks of “unicorn” startups with a valuation of more than $1bn.
– The funds will enable the company to broaden its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics.
– Mammoth’s CRISPR platform leverages the largest toolbox of novel Cas enzymes, driven by its proprietary protein discovery engine which leverages the natural diversity of life.

– bluebird bio, Inc. announced that it has entered into an agreement for a $75m private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process.
– Proceeds from the financing will support ongoing R&D and commercialization investments for bluebird bio and for 2seventy bio, which plan to launch as independent companies in October 2021.
– bluebird plans to complete the spin-off of 2seventy in October 2021, subject to customary conditions, including effectiveness of the Form 10, a favorable opinion from the IRS with respect to the tax-free nature of the transaction, and final approval from bluebird’s Board of Directors.

– Genome Medical, the leading nationwide genomic care delivery company, announced the closing of a $60m Series C financing to accelerate commercial traction and advance its mission of transforming health care for all through genomic medicine.
– These strategic initiatives solidify its position as the preeminent technology-enabled provider of genetic health services and genomic insights.
– Genome Medical will use the financing proceeds to expand its team and further enhance the development of its configurable technology solutions to provide innovative and efficient genomic medicine programs.
– The company will continue to build out its full suite of physician services, test ordering capabilities and guidelines-based care plans to ensure comprehensive, seamless care for patients.

– Strata Oncology, Inc. from Ann Arbor develops a comprehensive genomic profiling platform to deliver a portfolio of treatment selection tests for solid tumors.
– Series C $90m financing was led by Wellington Management and joined by other new investors.
– The new investment will be used to accelerate the company’s pipeline of novel RNA-based treatment selection tests for solid tumors.

– Deep Genomics announced the closing of a $180m Series C financing round.
– The round was led by SoftBank Vision Fund 2 and includes participation from new investors, Canadian Pension Plan Investment Board, Fidelity Management & Research Company, Alexandria Venture Investments, and existing investors Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures.
– Deep Genomics uses AI and machine learning to program and prioritize transformational RNA therapeutics for genetic diseases.
– The company has leveraged its strategic geographical advantage by combining its teams in Toronto, the birthplace of deep learning and the fastest growing technology hub in North America, with the Boston-Cambridge biotechnology hub, by hiring Jeffrey Brown, PhD, as VP of Preclinical Research, Ferdinand Massari, MD, as Chief Medical Officer, and Amanda Kay, PhD, as Chief Business Officer.

– Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced the final close of its Series A financing, at $10 million.
– The round was led by Sofinnova Partners, a leading European life sciences venture capital firm specialized in healthcare and sustainability.
– Protera is currently scaling-up its manufacturing process and validating its protein-based ingredients with several multinational companies.
– In particular, the financing will fast-track the scale up of protera guard™, a protein that extends the shelf-life of foods and replaces widely used chemical ingredients, with an efficient natural alternative.

– MiNA Therapeutics Limited is a London, UK-based provider of small activating RNA therapeutics.
– Company received $15m equity investment from Eli Lilly and Company.
– The funds will be used to advance and expand its internal pipeline of saRNA therapeutics.

– Incisive Genetics Inc. closed its $2.5 million seed financing.
– The financing syndicate was led by investors Noel Hall and Sandra MacPherson of the MacHall group and Haig Farris, OC.
– This funding will enable Incisive Genetics to develop its manufacturing process and capabilities, advance key studies to enhance its gene editing delivery platform technology, and further add to its intellectual property portfolio.

– BillionToOne, Inc. from Menlo Park develops molecular diagnostics company.
– The company closed a $55m Series B funding round.
– The round was led by existing investor Hummingbird Ventures and incoming investor Four Rivers Group with participation from Neotribe Ventures, Norwest Venture Partners, Y Combinator, and Libertus Capital.
– The new investment will be used to expand the company’s clinical lab and commercial team nationwide.

– Apton Biosystems, Inc. from Pleasanton, CA develops Super-Res sequencing and single-molecule detection systems for large-scale clinical applications such as early cancer detection and population sequencing.
– The company closed a $24m Series A financing.
– The round was led by Kern Capital with participation by new and existing investors including Casdin Capital and Khosla Ventures.
– The company intends to use the funds to continue developing its Super-Res sequencing and single-molecule proteomics detection systems.

– Insilico Medicine announced that it has closed a $255m Series C.
– The financing led by Warburg Pincus, and participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors including CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.
– The financing will be used to progress Insilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

– Helix is a San Mateo CA-based population genomics and COVID-19 testing company.
– The company raised $50m in Series C funding.
– The round was led by Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic and Temasek.
– The new investment will be used to accelerate the company’s population genomics platform across health systems, life sciences companies and to continue COVID-19 testing and viral surveillance efforts.

– Genoox is a Palo Alto in CA-based driven genomic data platform provider.
– The company raised $8m in funding.
– The round was led by IN Venture, a Sumitomo Corporation backed venture fund, with participation from Infinity Medical and existing investors Inimiti, Glilot Capital and Triventures.
– The new funding will be used to expand its community of genetic professional users and enhance the network effect created by sharing genetic insights on its platform.

– GenapSys is a company developing a highly accurate and scalable electronic sequencing platform.
– The company raised $70m in Series D equity financing.
– The investors in the round included Farallon Capital Management, L.L.C., Soleus Capital, an affiliate of PBM Capital, and additional new investors.
– The proceeds from this financing will be used to continue advancing GenapSys’ semiconductor based next-generation sequencing (NGS) platform.

– BroadOak Capital Partners has invested in KromaTiD.
– KromaTiD’s sales and operations are rapidly accelerating, driven by growing market adoption of their products and services, such as the recently launched dGH In-Site™ and dGH SCREEN™ products for gene editing and gene therapy applications.
– This capital will be used to accelerate commercialization, support ongoing product development, and to increase capacity to meet growing demand.
– KromaTiD’s directional Genomic Hybridization™, or dGH™, today provides the genomic structural context necessary to optimize gene editing strategies for research and clinical purposes, such as therapeutic gene editing based on CRISPR technologies, requiring measurements that can only be made with a single cell, genome-wide analysis provided by dGH™.

– Molecular Assemblies is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products.
– The company announced that it has closed an oversubscribed $24m Series A financing with significant investment from Agilent Technologies, iSelect Fund, Codexis, Alexandria Venture Investments, and Argonautic Ventures.

– C2i Genomics, a cancer detection company, raised $100m in Series B funding.
– The round was led by Casdin Capital and joined by new investors including New Enterprise Associates (NEA), and existing investors including Sequoia Capital, and others.
– The company plans to use the funding to expand its research and development efforts.

– Legacy, the premier digital fertility clinic for men, today announced $10m in Series A funding led by FirstMark Capital.
– Rick Heitzmann, founder and partner at FirstMark Capital, who is a leader in digital health and has led investment across healthcare including the Series A funding for Ro (officially known as Roman Health Ventures), will join the Legacy Board.
– This milestone marks over $15m in funds raised from a top-tier group of investors that also includes Bain Capital Ventures, Section 32, Y Combinator, TQ Ventures, and Tribe Capital.

– C2i Genomics from New York, NY provides a cloud-based cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease.
– The company raised $100m in financing.
– The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others.
– The new investment will be used to accelerate the company’s clinical development and commercialization of its C2-Intelligence Platform.

– Entrada Therapeutics from Boston develops intracellular biologics to treat devastating diseases.
– The company closed a $116m Series B financing.
– The round was led by Wellington Management Company and joined by Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority (“QIA”), Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures and one undisclosed global investment firm.
– Existing investors 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital also participated in the financing.
– The new investment will be used to advance its pipeline to the clinic.

– ElevateBio is a Cambridge, Mass.-based cell and gene therapy technology company focused on advancing new cell and gene therapies.
– Company raised $525m in Series C funding.
– The round was led by Matrix Capital Management with participation from new investors SoftBank Vision Fund 2 and Fidelity Management and Research Company and existing investors MPM Capital, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital, The Invus Group, Emerson Collective, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures, iTochu, and a large insurance company.

– Variantyx, a Boston, MA-based hereditary disease testing company, secured $20M in Series C funding.
– The round was led by GHS Fund (Quark Venture LP and GF Securities) and includes new investor, IBM Ventures and current investors, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners.
– In conjunction with the funding, Zafrira Avnur, PhD, Quark Venture Chief Scientific Officer & Partner, will join the Variantyx board of directors.
– The company intends to use the funds for development of its tumor diagnostic solutions and the expansion of sales.

– Valor Ventures Fund 2 is pleased to announce its seventh investment, a $1.75m Series Seed financing of Allelica, Inc.
– Valor General Partner Gary Peat joins the Allelica board of directors.
– In addition to lead investor Valor Ventures, participants in the round included AI-focused venture fund Pi Campus and prestigious genetics research institution Medical Genetics Center (MGZ) in Munich as a strategic investor.
– Allelica brings precision medicine into mainstream clinical practice through a Software-as-a-Service platform for the prediction of complex, genetic diseases using proprietary polygenic risk scores.
– With major customers across three continents, Allelica is poised to be the first mass adoption of precision medicine.

– L7 Informatics announced it raised $13m in Series B financing.
– The round was supported by previous investors along with several new investors, including Phoenix Venture Partners.
– The proceeds from the financing will be used to accelerate the commercialization of L7’s Enterprise Science Platform™ (L7|ESP™).

– eGenesis from Cambridge, Mass. develops human-compatible organs, tissues, and cells.
– The company raised $125m in Series C funding.
– Backers included Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management, and Osage University Partners and existing investors Leaps by Bayer, Fresenius Medical Care Ventures, ARCH Venture Partners, Wellington Partners, Khosla Ventures, and Alta Partners.

– Phase Genomics, Inc. announced the receipt of a $1.7MM grant from the National Institute of Allergy and Infectious Diseases (NIAID).
– This funding will fuel the commercialization of a first-in-class solution for the discovery of DNA viruses, employing a novel reagent kit and robust software platform that leverages Phase Genomics’ proprietary Hi-C technology.
Phase Genomics is also funded by revenue from sales of its proximity ligation (Hi-C) kits, scientific services, and computational analysis.